Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT06502977
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Army Medical University, People's Liberation Army, Chongqing, Chongqing, China
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 13
- Registration Number
- NCT06468826
- Locations
- 🇺🇸
Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 231
- Registration Number
- NCT06438263
- Locations
- 🇺🇸
Fortrea Clinical Research Unit - Dallas, Dallas, Texas, United States
🇺🇸Fortrea Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States
🇺🇸Fortrea Clinical Research Unit Inc. - Madison, Madison, Wisconsin, United States
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
- Conditions
- Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 154
- Registration Number
- NCT06430866
- Locations
- 🇧🇬
University Multiprofile Hospital for Active Treatment Sofiamed, Sofia, Bulgaria
🇨🇱Centro de Investigaciones Clinicas Vina del Mar Ltda., Vina del Mar, Region De Valparaiso, Chile
🇨🇱Clinica Santa Maria, Santiago, Region Metropolitana, Chile
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT06411860
- Locations
- 🇬🇧
Fortrea Clinical Research Unit Limited - Leeds, Leeds, United Kingdom
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT06389578
- Locations
- 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
🇺🇸Barnes Jewish Hospital Washington University, Saint Louis, Missouri, United States
🇺🇸Neuro-Eye Clinical Trials, Bellaire, Texas, United States
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 428
- Registration Number
- NCT06376045
- Locations
- 🇺🇸
Kern Research Inc, Bakersfield, California, United States
🇺🇸Orso Health Inc, La Jolla, California, United States
🇺🇸Imax Clinical Trials, La Palma, California, United States
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
- Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 188
- Registration Number
- NCT06360354
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
- Conditions
- Thoracic TumorsNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 500
- Registration Number
- NCT06333951
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Translational Research in Oncology US Inc, Trio Central Pharmacy, Los Angeles, California, United States
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT06332014
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China